Victoria regained top spot for SAS-B approvals from Queensland in February as the Therapeutic Goods Administration rubber stamped 12,301 applications, up 16% on January.
The garden state was responsible for 5,168 of medicinal cannabis approvals in the month, overtaking Queensland which generated 3,965. As in previous months, New South Wales came in third with 2,601.
High-THC, category 5 medicine once again contributed almost half the approvals at 6,057, with 43% of those (2,598) being for men aged 18 to 44.
Overall, the gender split was 60:40 in favour of men.
Chronic pain, anxiety and sleep disorder were the most common indications for which a SAS-B approval was granted, followed by depression, PTSD and ADHD.
Oral solutions remained the most popular delivery format, accounting for 47% of approvals, followed by flower at 37%, inhalation (8%) and pastilles, which displaced capsules in fourth place with 3% of the market.
The SAS-B applications were generated by 906 prescribers.